In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease
The recent coronavirus disease (COVID-19) outbreak in Wuhan, China, has led to millions of infections and the death of approximately one million people. No targeted therapeutics are currently available, and only a few efficient treatment options are accessible. Many researchers are investigating active compounds from natural plant sources that may inhibit COVID-19 proliferation. Flavonoids are generally present in our diet, as well as traditional medicines and are effective against various diseases. Thus, here, we reviewed the potential of flavonoids against crucial proteins involved in the coronavirus infectious cycle. The fundamentals of coronaviruses, the structures of SARS-CoV-2, and the mechanism of its entry into the host's body have also been discussed. In silico studies have been successfully employed to study the interaction of flavonoids against COVID-19 Mpro, spike protein PLpro, and other interactive sites for its possible inhibition. Recent studies showed that many flavonoids such as hesperidin, amentoflavone, rutin, diosmin, apiin, and many other flavonoids have a higher affinity with Mpro and lower binding energy than currently used drugs such as hydroxylchloroquine, nelfinavir, ritonavir, and lopinavir. Thus, these compounds can be developed as specific therapeutic agents against COVID-19, but need further in vitro and in vivo studies to validate these compounds and pave the way for drug discovery.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
---|---|
Enthalten in: |
Molecules (Basel, Switzerland) - 27(2022), 19 vom: 27. Sept. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Kashyap, Piyush [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 17.10.2022 Date Revised 07.12.2022 published: Electronic Citation Status MEDLINE |
---|
doi: |
10.3390/molecules27196374 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM347499759 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM347499759 | ||
003 | DE-627 | ||
005 | 20231226033955.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/molecules27196374 |2 doi | |
028 | 5 | 2 | |a pubmed24n1158.xml |
035 | |a (DE-627)NLM347499759 | ||
035 | |a (NLM)36234910 | ||
035 | |a (PII)6374 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Kashyap, Piyush |e verfasserin |4 aut | |
245 | 1 | 0 | |a In Silico Evaluation of Natural Flavonoids as a Potential Inhibitor of Coronavirus Disease |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 17.10.2022 | ||
500 | |a Date Revised 07.12.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The recent coronavirus disease (COVID-19) outbreak in Wuhan, China, has led to millions of infections and the death of approximately one million people. No targeted therapeutics are currently available, and only a few efficient treatment options are accessible. Many researchers are investigating active compounds from natural plant sources that may inhibit COVID-19 proliferation. Flavonoids are generally present in our diet, as well as traditional medicines and are effective against various diseases. Thus, here, we reviewed the potential of flavonoids against crucial proteins involved in the coronavirus infectious cycle. The fundamentals of coronaviruses, the structures of SARS-CoV-2, and the mechanism of its entry into the host's body have also been discussed. In silico studies have been successfully employed to study the interaction of flavonoids against COVID-19 Mpro, spike protein PLpro, and other interactive sites for its possible inhibition. Recent studies showed that many flavonoids such as hesperidin, amentoflavone, rutin, diosmin, apiin, and many other flavonoids have a higher affinity with Mpro and lower binding energy than currently used drugs such as hydroxylchloroquine, nelfinavir, ritonavir, and lopinavir. Thus, these compounds can be developed as specific therapeutic agents against COVID-19, but need further in vitro and in vivo studies to validate these compounds and pave the way for drug discovery | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a ACE2 | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a Mpro | |
650 | 4 | |a flavonoids | |
650 | 4 | |a in silico studies | |
650 | 7 | |a Antiviral Agents |2 NLM | |
650 | 7 | |a Flavonoids |2 NLM | |
650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
650 | 7 | |a Lopinavir |2 NLM | |
650 | 7 | |a 2494G1JF75 |2 NLM | |
650 | 7 | |a Rutin |2 NLM | |
650 | 7 | |a 5G06TVY3R7 |2 NLM | |
650 | 7 | |a Diosmin |2 NLM | |
650 | 7 | |a 7QM776WJ5N |2 NLM | |
650 | 7 | |a Hesperidin |2 NLM | |
650 | 7 | |a E750O06Y6O |2 NLM | |
650 | 7 | |a Nelfinavir |2 NLM | |
650 | 7 | |a HO3OGH5D7I |2 NLM | |
650 | 7 | |a Ritonavir |2 NLM | |
650 | 7 | |a O3J8G9O825 |2 NLM | |
700 | 1 | |a Thakur, Mamta |e verfasserin |4 aut | |
700 | 1 | |a Singh, Nidhi |e verfasserin |4 aut | |
700 | 1 | |a Shikha, Deep |e verfasserin |4 aut | |
700 | 1 | |a Kumar, Shiv |e verfasserin |4 aut | |
700 | 1 | |a Baniwal, Poonam |e verfasserin |4 aut | |
700 | 1 | |a Yadav, Yogender Singh |e verfasserin |4 aut | |
700 | 1 | |a Sharma, Minaxi |e verfasserin |4 aut | |
700 | 1 | |a Sridhar, Kandi |e verfasserin |4 aut | |
700 | 1 | |a Inbaraj, Baskaran Stephen |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Molecules (Basel, Switzerland) |d 2004 |g 27(2022), 19 vom: 27. Sept. |w (DE-627)NLM172073448 |x 1420-3049 |7 nnns |
773 | 1 | 8 | |g volume:27 |g year:2022 |g number:19 |g day:27 |g month:09 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/molecules27196374 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 27 |j 2022 |e 19 |b 27 |c 09 |